$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Using the method described here, we injected two groups of adult female rats (250−300 g; n = 10/group) with either a single bolus of phosphate-buffered saline PBS or 300 µg of ASO targeting the long non-coding (linc) RNA Malat1; in our lab we routinely use the Malat1 ASO as a tool compound, because Malat1 is expressed ubiquitously and at high levels in all tissues14, including brain and spinal cord. The Malat1 ASO works via an RNaseH1-mediated mechanism15 that degrades the RNA, leading to knockdown (KD). In the experiment described here, we collected different regions of the brain (i.e., cerebral cortex, striatum and cerebellum) as well as the lumbar segment of the spinal cord, two weeks after delivery of the ASO. RNA from each of the collected region was then extracted and analyzed via qPCR, to assess the levels of expression of the Malat1 RNA.
When the tested agent is an ASO, we recommend to: 1) always collect multiple regions of the CNS, in order to compare ASO efficacy; 2) given the technical complexity of the surgical method, we recommend to include a positive control group, where a compound with well-established pharmacokinetic and pharmacodynamic properties (i.e., Malat1 ASO in our lab) is tested in parallel to the test agent; this will provide information on the effectiveness of the surgeries, should unexpected or unexplainable results be obtained (e.g., lack of or insufficient RNA regulation).
In the experiment described here, we obtained very good KD in all regions collected, as shown in Figure 3. However, we did observe some degree of regional variability with the spinal cord showing the highest percentage of KD (cerebral cortex = 87% KD, striatum = 77% KD, cerebellum = 74% KD, spinal cord = 94% KD). We have not accessed in vivo knockdown efficiency earlier than 2 weeks post-surgery. In our experiences with several ASOs, we detected significant knockdown of the target genes up to 6−8 weeks post-surgery (data not shown). A time-course study should be carried out if the precise time-dependent knockdown efficiency of a given ASO is of interest.

Figure 1: Customized material and catheter sets used in intrathecal injections. (A) The catheter/wire assembly (v) is made by inserting stylet wire (ii) into the lumen of PE-10 catheter (i). The cannula/needle assembly (vi) is made by inserting a 23 G needle into the lumen of the guide cannula (iii). (B) The delivery catheter assembly (v) is made by connecting tubing adapter to one end of the PE-50 catheter and connecting the cut 30 G needle into the other end using a piece of PE-10 catheter (ii) as an adaptor. During the surgery, the 30 G needle end of the delivery catheter assembly (v) is connected to the top of the implanted catheter (vi), after the other end of the implanted catheter is inserted into the intrathecal space of the animal. Please click here to view a larger version of this figure.

Figure 2: Identification of injection site and incision line. (A) With the abdominal of the rat supported by a 50 mL conical tube, the two pits between muscles above the pelvis are easily seen (arrows). (B) With one hand holding the pits, use the other hand to gently press and feel the spine and find the intervertebral space between the L5 and L6 vertebrae, i.e., the injection site (* in panel A). The dotted line in panel A shows the incision line with the injection site at its center. Please click here to view a larger version of this figure.

Figure 3: A single bolus IT injection of ASOs reduces rat Malat1 in vivo. We injected a single bolus of either PBS or 300 µg of Malat1 ASO; two weeks after the surgery we collected different regions of the CNS and quantified the expression levels of Malat1 RNA. We obtained good KD of Malat1 RNA in all regions analyzed, with some variability among regions (cerebral cortex = 87% KD, striatum = 77% KD, cerebellum = 74% KD, spinal cord = 94% KD; error bars = ± SEM). Please click here to view a larger version of this figure.